HTG grants Firalis rights to NGS-based theranostics product for RA

HTG Molecular Diagnostics Inc. (NASDAQ:HTGM) granted Firalis S.A. (Huningue, France) non-exclusive, worldwide rights to commercialize next-generation sequencing (NGS)-based theranostics and services to predict the response rheumatoid arthritis patients will have to anti-TNFα therapy. The deal also includes other products and services for "mRNA profiling of inflammatory-autoimmune disorders."...